Melanocortin receptors in GtoPdb v.2023.1

  • Vanni Caruso University of Tasmania https://orcid.org/0000-0002-0523-6149
  • Biao-Xin Chai University of Michigan
  • Adrian J. L. Clark St. Bartholomew's Hospital
  • Roger D. Cone University of Michigan
  • Alex N. Eberle Universitsspital
  • Sadaf Farooqi University of Cambridge
  • Tung M. Fong Vyluma Inc
  • Ira Gantz Merck & Co. Inc.
  • Carrie Haskell-Luevano University of Minnesota
  • Victor J. Hruby University of Arizona
  • Kathleen G. Mountjoy University of Auckland
  • Colin Pouton University of Bath
  • Helgi Schiöth Uppsala University
  • Jeffrey B. Tatro New England Medical Center Hospital
  • Jarl E. S. Wikberg Uppsala University

Abstract


Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [41]) are activated by members of the melanocortin family (α-MSH, β-MSH and γ-MSH forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH). Endogenous antagonists include agouti and agouti-related protein. ACTH(1-24) was approved by the US FDA as a diagnostic agent for adrenal function test. setmelanotide was approved by the US FDA for weight management in patients with POMC, PCSK1 or LEPR defiency, bremelanotide was approved by the US FDA for generalized hypoactive sexual desire disorder in premenopausal women, and NDP-MSH (afamelanotide) was approved by the EMA for the treatment of erythropoietic protoporphyria. Several synthetic melanocortin receptor agonists are under clinical development.

Published
26-Apr-2023
How to Cite
Caruso, V., Chai, B.-X., Clark, A. J. L., Cone, R. D., Eberle, A. N., Farooqi, S., Fong, T. M., Gantz, I., Haskell-Luevano, C., Hruby, V. J., Mountjoy, K. G., Pouton, C., Schiöth, H., Tatro, J. B. and Wikberg, J. E. S. (2023) “Melanocortin receptors in GtoPdb v.2023.1”, IUPHAR/BPS Guide to Pharmacology CITE, 2023(1). doi: 10.2218/gtopdb/F38/2023.1.
Section
Summaries